Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial

BACKGROUND: The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and temozolomide (TMZ) chemotherapy in preclinical glioblastoma models but brain penetration was poor. Clinically, PARP inhibitors exacerbate the hematological side effects of TMZ. The OPARATIC trial was cond...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Hanna, Catherine, Kurian, Kathreena M, Williams, Karin, Watts, Colin, Jackson, Alan, Carruthers, Ross, Strathdee, Karen, Cruickshank, Garth, Dunn, Laurence, Erridge, Sara, Godfrey, Lisa, Jefferies, Sarah, McBain, Catherine, Sleigh, Rebecca, McCormick, Alex, Pittman, Marc, Halford, Sarah, Chalmers, Anthony J
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2020
Ämnen:
Clinical Investigations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7746945/
https://ncbi.nlm.nih.gov/pubmed/32347934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa104
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk